MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-HP-11-0002828
Crius Life Sciences Private Limited - healthcare in Nalagarh, Himachal Pradesh, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹116.77 Cr
▲ 3% YoY
Net profit · FY 2025
₹8.07 Cr
Net margin 6.9%
EBITDA · FY 2025
₹14.43 Cr
EBITDA margin 12.4%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹5 Cr
Issued & subscribed
Open charges
₹54.3 Cr
Secured borrowings
Company age
10 yrs
Est. 2016
Employees · EPFO
261
Provident fund records
About Crius Life Sciences Private Limited
Data last updated:
Crius Life Sciences Private Limited is a private limited company based in Nalagarh, Himachal Pradesh, India. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 02 February 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN U24232HP2016PTC001137. Its GSTIN is 02AAGCC3459E1Z1 (Himachal Pradesh). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It is led by directors including Chinni Venkata Subbarao and Dalip Singh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Nalagarh, Himachal Pradesh.
As per the financials filed for FY 2025, the company reported a revenue of ₹116.77 Cr, a growth of 3% compared to the previous year. For the same year it recorded a net profit of ₹8.07 Cr (net margin 6.9%) and EBITDA of ₹14.43 Cr (EBITDA margin 12.4%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years and 17% over five years.
The company has about 261 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹54.3 Cr on record. Court records list 4 cases involving the company, including 3 filed by the company and 1 filed against it; 1 case is pending. The company has 3 deals on record (2 rights issues, 1 funding round), with disclosed funding of ₹1.2 Cr; the latest was in December 2021. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Zen Pharma Private Limited with revenue of ₹118.25 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 12 overdue payments to 7 micro and small suppliers.
Crius Life Sciences Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0002828). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website criuslife.com.
Company details
CIN U24232HP2016PTC001137
Registration Number 001137
Incorporation Date 02 February 2016
ROC Himachal Pradesh
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HP-11-0002828
Recognitions & Rankings of Crius Life Sciences
Contact details
Crius Life Sciences Private Limited's registered office is in Nalagarh, Himachal Pradesh. Its website is criuslife.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressKhasra No. 1298/1190/474 And 1187/474, Mauza Malpur, Nalagarh, Himachal Pradesh, India – 173205
- IndustryHealthcare, Preventive Health Supplements
To see the full contact details of Crius Life Sciences Private Limited, buy the company report.
Comprehensive company report
Crius Life Sciences Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Crius Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Crius Life Sciences Private Limited, buy the company report.
Financials of Crius Life Sciences Private Limited
FY 2024 filings availableCrius Life Sciences Private Limited reported revenue of ₹116.77 Cr (up 3% YoY) for FY 2025.
Revenue · FY 2025
₹116.77 Cr ▲ 3%
Net profit · FY 2025
₹8.07 Cr margin 6.9%
EBITDA · FY 2025
₹14.43 Cr margin 12.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 3%
3 years · compounded
▲ 9%
5 years · compounded
▲ 17%
EBITDA CAGR growth
1 year
▲ 6%
3 years · compounded
▲ 10%
5 years · compounded
▲ 26%
Revenue has grown at a compounded annual rate (CAGR) of 17% over five years, including 3% growth in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹14.43 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.07 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.4% | ||||
| Net Profit Margin | 6.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Crius Life Sciences Private Limited, buy the company report.
Board of directors of Crius Life Sciences Private Limited
Crius Life Sciences has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chinni Venkata Subbarao | Director | 02 Feb 2016 | 10 Years 8 Months | Current |
| Dalip Singh | Director | 04 Mar 2022 | 4 Years 7 Months | Current |
| Birendra Chalaune | Director | 28 Mar 2017 | 9 Years 6 Months | Current |
Peer comparison
Crius Life Sciences Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zen Pharma Private Limited | ₹118.25 Cr (FY 2022) | 24.0% | Mumbai, Maharashtra, India | |||
| Anglo-French Drugs & Industries Limited | ₹117.99 Cr (FY 2025) | 18.0% | Mumbai, Maharashtra, India | |||
| Bioaltus Pharmaceuticals Private Limited | ₹117.77 Cr (FY 2025) | 26.0% | Thane, Maharashtra, India | |||
| Westcoast Pharmaceutical Works Limited | ₹117.56 Cr (FY 2024) | -3.0% | Ahmedabad, Gujarat, India | |||
| Crius Life Sciences Private Limitedthis company | ₹116.77 Cr (FY 2025) | ₹8.07 Cr | 6.9% | 3.0% | 261 | Nalagarh, Himachal Pradesh, India |
| Kerala State Drugs and Pharmaceuticals Ltd | ₹116.23 Cr (FY 2024) | 41.0% | Alappuzha, Kerala, India | |||
| Ar-Ex Laboratories Private Limited | ₹115.46 Cr (FY 2025) | 16.0% | Mumbai, Maharashtra, India | |||
| Pharose Remedies Limited | ₹115.39 Cr (FY 2025) | 4.0% | Punjab, India | |||
| Biogenetic Drugs Private Limited | ₹115.34 Cr (FY 2025) | -2.0% | Jaipur, Rajasthan, India |
To see the full peer comparison of Crius Life Sciences Private Limited, buy the company report.
Auditor
Crius Life Sciences Private Limited is audited by MOHINDER K SHARMA & CO for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MOHINDER K SHARMA & CO | FY 2024 | 009867N |
Shareholding
The shareholding of Crius Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Crius Life Sciences Private Limited, buy the company report.
Charges & borrowings
Open charges
₹54.3 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 May 2025 | 101100730 | Others | ₹20.39 Lakh | Open | |
| 28 Aug 2024 | 100978556 | Others | ₹71.63 Lakh | Open | |
| 10 May 2024 | 100929067 | Others | ₹5.75 Cr | Open | |
| 10 May 2024 | 100927829 | Others | ₹2.8 Cr | Open | |
| 20 Nov 2023 | 100836179 | Others | ₹20.29 Lakh | Open |
To see the full charge records of Crius Life Sciences Private Limited, buy the company report.
Total charge records: 14 View all charges
Deals & funding
Crius Life Sciences Private Limited has 3 deals on record (2 rights issues, 1 funding round), with disclosed funding of ₹1.2 Cr; the latest was in December 2021.
Total deals
3
Rights issues
2
Funding round
1
Disclosed funding
₹1.2 Cr
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2021 | Funding round | ₹1.2 Cr | Investors: 2 individuals |
| Mar 2021 | Rights issue | ₹1.8 Cr | Investors: an individual |
| Dec 2018 | Rights issue | ₹1.5 Cr | Investors: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Crius Life Sciences Private Limited has 4 court cases on record: 3 filed by Crius Life Sciences, 1 filed against it. 1 case is pending and 3 are disposed.
Total cases
4
Filed by the company
3
Filed against the company
1
Pending
1
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 1 | 1 |
| High courts | 1 | 0 | 0 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Solan, Himachal Pradesh | Cheque dishonour complaint | Filed by the company against M/S Winmark Healthcare Pvt. Ltd. | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons cases SS) | Filed against the company by an individual | Pending |
| District court, Solan, Himachal Pradesh | Execution petition | Filed by the company against M/S Inavars Biological Inc. and 1 other | Disposed |
| High Court, MAHARASHTRA | Court case (APL) | Filed by the company against The State of Maharashtra | Disposed |
To see the full case history of Crius Life Sciences Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Crius Life Sciences Private Limited was last rated by Crisil on 31 Dec 2019.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 31 Dec 2019 |
To see the full credit ratings and regulatory alerts of Crius Life Sciences Private Limited, buy the company report.
MSME payment delays
Crius Life Sciences Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 12 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 7)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Ideal Cures Private Limited | |||
| Jasco Paper Products | |||
| Konark Herbal and Health Care | |||
| an individual supplier |
To see the full MSME payment records of Crius Life Sciences Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Crius Life Sciences Private Limited has a workforce of 261 employees on its EPFO records as of Mar 29, 2025, across 1 active EPFO establishment.
Employee count
261
Active EPFO establishments
1
Employee growth
6.53%
GST
Crius Life Sciences has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AAGCC3459E1Z1 | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAGCC3459E1ZZ | Punjab | Active | 01 Mar 2022 |
To see the full GST registrations and return filing status of Crius Life Sciences Private Limited, buy the company report.
Recent activity
Crius Life Sciences Private Limited has 8 board changes on record since 2016: 3 appointments and 5 cessations. The latest: Chandan Kumar Barik ceased to be Director on 09 May 2024.
Charges
A charge with Others amounted to Rs. 0.20 Cr with Charge ID 101100730 was registered on 29 May 2025.
Charges
A charge with Others of Rs. 17.00 Cr registered on 22 Jun 2017 with Charge ID 100122832 was modified on 28 Jan 2025.
AGM
Crius Life Sciences Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 0.72 Cr with Charge ID 100978556 was registered on 28 Aug 2024.
Charges
A charge with Others amounted to Rs. 5.75 Cr with Charge ID 100929067 was registered on 10 May 2024.
Charges
A charge with Others amounted to Rs. 2.80 Cr with Charge ID 100927829 was registered on 10 May 2024.
Ceased
Chandan Kumar Barik ceased to be Director.
Filing
Crius Life Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Himachal Pradesh.
Ceased
Surya Tej Chinni ceased to be Director.
Charges
A charge with Others amounted to Rs. 0.20 Cr with Charge ID 100836179 was registered on 20 Nov 2023.
Charges
A charge with Others amounted to Rs. 0.20 Cr with Charge ID 100836173 was registered on 20 Nov 2023.
Charges
A charge with Others amounted to Rs. 1.98 Cr with Charge ID 100827429 was registered on 06 Nov 2023.
15 earlier events are in the company report.
Frequently asked questions
Crius Life Sciences is an active private limited company based in Nalagarh, Himachal Pradesh, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 02 February 2016 (10+ years old) and is registered under CIN U24232HP2016PTC001137.
Crius Life Sciences has 3 current directors:
- Chinni Venkata Subbarao - Director
- Dalip Singh - Director
- Birendra Chalaune - Director
The latest financial statements of Crius Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Crius Life Sciences is 02AAGCC3459E1Z1, registered in Himachal Pradesh. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 03AAGCC3459E1ZZ (Punjab).
The CIN (Corporate Identification Number) of Crius Life Sciences is U24232HP2016PTC001137. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Crius Life Sciences has 4 court cases on record: 3 filed by the company and 1 filed against it. 1 is pending. Most are in the district courts.
Crius Life Sciences was incorporated on 02 February 2016, making it 10+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.
Crius Life Sciences has 3 deals on record (2 rights issues, 1 funding round), with disclosed funding of ₹1.2 Cr; the latest was in December 2021.
The peers of Crius Life Sciences by revenue are Zen Pharma Private Limited, Anglo-French Drugs & Industries Limited, Bioaltus Pharmaceuticals Private Limited, Westcoast Pharmaceutical Works Limited, Kerala State Drugs and Pharmaceuticals Ltd and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Chandan Kumar Barik ceased to be Director on 09 May 2024. Surya Tej Chinni ceased to be Director on 17 Jan 2024. Tarun Pratap Singh ceased to be Director on 14 May 2022. Crius Life Sciences has 8 board changes on record in total.
Yes, Crius Life Sciences is registered as a medium enterprise under Udyam registration (number: UDYAM-HP-11-0002828).
Crius Life Sciences has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 12 overdue payments to 7 micro and small suppliers. The latest return was filed on 30 May 2019.